PatientsCann UK | What the McCarthy Tribunal Decision Really Says Skip to content News & Analysis Workplace Rights Driving & the Law What the McCarthy tribunal decision really says about medical cannabis, driving and work Reduced to a headline, this case looks like a ruling that medical cannabis patients cannot work or drive. That is not what the tribunal decided. Here is what the judgment in Miss L McCarthy v Kirklees Metropolitan Council actually found, and what it means for patients and employers. PatientsCann UK News & Advocacy Employment tribunal analysis On this page Context Not a blanket ban Treated differently? Missing information Occupational health Where it went wrong The wider lesson The reporting problem Bottom line Letter template References Please note This article is general information and analysis of a published employment tribunal decision. It is not legal or medical advice. If you face a workplace or driving issue involving your prescription, seek advice specific to your circumstances. Why this matters Not a blanket ban The tribunal did not find that patients are automatically unfit to work or drive. A narrow question It was about one claimant, in a safety-sensitive role, against a specific background. Misreported Headlines framing this as “cannabis means you cannot work” distort the judgment. Background Context: why this case has caused concern At first glance, the tribunal decision in Miss L McCarthy v Kirklees Metropolitan Council looks like exactly the sort of case the medical cannabis community has feared: a patient has a lawful medical cannabis prescription, wants to return to work, and the outcome appears to suggest that medical cannabis use means you cannot safely work or drive as part of your job. Read through that lens, and reduced to a newspaper headline, it is easy to see why people are worried. But that is not what the tribunal actually decided. The important distinction is that the tribunal did not find that medical cannabis patients are automatically unfit for work or unable to drive. It found that, in this particular situation, the employer was entitled to pause and seek further information before allowing a full return to normal duties, because the job involved vulnerable service users and some driving, and because the employer did not yet have enough role-specific and prescription-specific information to complete its safety assessment. The claimant had a diagnosis of Emotionally Unstable Personality Disorder / Borderline Personality Disorder, which the employer knew about. She had also experienced a serious mental-health crisis in September 2023, had been admitted to psychiatric hospital, and was absent from work. During this period, she also disclosed previous illegal drug use, including cocaine and cannabis. She later obtained a private medical cannabis prescription, and provided her employer with some information about medical cannabis, including clinic correspondence and external guidance. At around the same time, the employer received a PIPOT safeguarding referral involving alleged aggressive or threatening behaviour reported through NHS and police channels. Because the claimant worked with vulnerable service users, the employer treated this as a significant safeguarding issue and required a further enhanced DBS check. So the tribunal was not looking at a simple question of “can someone prescribed medical cannabis work and drive?” It was looking at a much narrower question: was this employer acting unlawfully when it paused, asked for more information, sought occupational-health advice, considered safeguarding concerns, and managed a staged return to work in this specific set of circumstances? The tribunal answered no. The key point This was not a blanket ban case A central concern is that the decision might create a precedent that employers can say “there is not enough information about medical cannabis, so we cannot safely let you drive.” But that is not what the tribunal found. The claimant alleged that she was told in April 2024 that she could not drive as part of her duties. The tribunal rejected that allegation. It found that no driving prohibition was imposed. There had been discussion about medical cannabis, driving law, and the statutory defence where medication is prescribed and taken as directed, but the tribunal found the employer did not ban her from driving. That is important. The case does not stand for the proposition that an employer can automatically prevent a medical cannabis patient from driving for work. It stands for the much narrower proposition that, where there are specific safety-related questions, an employer may ask for relevant information before reaching a decision. UK driving law also does not impose a blanket ban on people taking prescribed medicines. GOV.UK explains that a person may drive after taking certain prescribed medicines if they have been prescribed them, have followed healthcare advice, and the medicine is not causing them to be unfit to drive. The lawful position. Not “medical cannabis equals no driving,” but rather: a patient may drive if the medicine is lawfully prescribed, taken as directed, and they are not impaired or unfit to drive. Discrimination argument Why the tribunal did not see this as cannabis being treated differently The claimant argued that the employer had no business asking about her driving while taking prescribed medication, and that other medicines were not treated in this way. The tribunal rejected that argument. It accepted evidence from HR that similar enquiries would be made if any employee’s prescribed medication was suspected to affect their ability to perform their duties safely. This is the crucial distinction. The tribunal did not say “medical cannabis is uniquely risky, so employers can restrict it.” It said, in effect, if any medication may affect safe performance in a particular role, the employer can make proportionate enquiries. That matters because many prescribed medicines can affect driving, judgement, alertness, coordination, or reaction time, for example opioids, benzodiazepines, sedatives, strong painkillers, some psychiatric medications, and other controlled medicines. GOV.UK’s drug-driving guidance is framed around impairment and prescribed medicines generally, not medical cannabis alone. The problem would be different if an employer scrutinised medical cannabis patients but ignored comparable risks from other prescribed medicines. That could potentially

<p>The post McCarthy Tribunal Decision first appeared on PatientsCann UK®.</p>